Accueil | Merck Canada

Prix Merck Le patient d’abord: La période de candidature est maintenant ouverte jusqu’au 6 décembre!

Merck Canada accueille favorablement l’initiative relative aux produits biosimilaires adoptée par le gouvernement de la Colombie-Britannique

PREMIER ET SEUL INHIBITEUR DE LA PARP, LYNPARZA^® (OLAPARIB) EST APPROUVÉ POUR LE TRAITEMENT D’ENTRETIEN DE PREMIÈRE INTENTION DU CANCER DE L’OVAIRE DE STADE AVANCÉ AVEC MUTATION D’UN GÈNE BRCA Le 8 mai 2019

Nouveau traitement maintenant offert au Canada pour les patients ayant récemment reçu un diagnostic de cancer du poumon à un stade avancé

Merck Biosimilaires
est avec vous à chaque étape

Pour en savoir plus

Nous inventons depuis toujours et nous ne cesserons jamais de le faire. Nos efforts ne visent qu’un seul et unique but, le plus important, assurer la vie.

Voir nos dernières nouvelles

Divulgation volontaire des paiements aux professionnels de la santé et aux organisations de soins de santé

Forward-Looking Statement

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.